[{"polarity": 0, "orig_sen": "METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m\u00b2 i.v. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of hepatic arterial infusion (HAI) of gemcitabine plus oxaliplatin as second-line treatment for unresectable locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed the outcome of 12 consecutive patients with unresectable locally advanced intrahepatic cholangiocarcinoma treated with HAI of gemcitabine (1,000 mg/m(2) over 30 min) followed by oxaliplatin (100 mg/m(2) over 2 h), which was repeated every 2 weeks. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: HAI combining gemcitabine and oxaliplatin showed promising efficacy and safety as second-line treatment for locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CASE REPORT: We report a case of RPLS associated with concurrent bevacizumab (Avastin), gemcitabine, and oxaliplatin use for unresectable intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "The feasibility and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIM: To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma. ", "drug": "Bevacizumab", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Bevacizumab", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CASE REPORT: We report a case of RPLS associated with concurrent bevacizumab (Avastin), gemcitabine, and oxaliplatin use for unresectable intrahepatic cholangiocarcinoma. ", "drug": "Bevacizumab", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "Sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet derived growth factor receptor-\u03b2, B-Raf proto-oncogene, serine/threonine kinase and C-Raf proto-oncogene, serine/threonine kinase, is a novel reference standard for the treatment of advanced hepatocellular carcinoma. ", "drug": "sorafenib", "disease": "Hepatocellular carcinoma"}, {"polarity": 1, "orig_sen": "Sorafenib, a multikinase inhibitor, which can competitively inhibit RAF/MEK/ERK pathway, human vascular endothelial growth factor receptors (VEGFR2, VEGFR3) platelet-derived growth factor receptor beta (PDGFR), Flt3, and C-kit receptors, has been successfully applied for solid tumors such as renal cancer and hepatocellular carcinoma. ", "drug": "sorafenib", "disease": "Hepatocellular carcinoma"}, {"polarity": 0, "orig_sen": " The aim of the study was to evaluate the expression of activated mammalian rapamycin (mTOR) and its downstream effectors, phosphorylated p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1), in intrahepatic cholangiocarcinomas (ICC), in order to strengthen the rationale for targeted therapy using mTOR inhibitors in patients with ICC. ", "drug": "Rapamycin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "We investigated the status of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), phosphorylated (p) AKT1 (p-AKT1), p-mammalian target of rapamycin (p-MTOR), p-p70 ribosomal protein S6 kinase (p-RPS6KB2) and p-eukaryotic initiation factor 4E-binding protein-1 (p-EIF4EBP1) in 101 intrahepatic cholangiocarcinomas by immunohistochemistry. ", "drug": "Rapamycin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m\u00b2 i.v. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of hepatic arterial infusion (HAI) of gemcitabine plus oxaliplatin as second-line treatment for unresectable locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed the outcome of 12 consecutive patients with unresectable locally advanced intrahepatic cholangiocarcinoma treated with HAI of gemcitabine (1,000 mg/m(2) over 30 min) followed by oxaliplatin (100 mg/m(2) over 2 h), which was repeated every 2 weeks. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: HAI combining gemcitabine and oxaliplatin showed promising efficacy and safety as second-line treatment for locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "The tumor was diagnosed as an unresectable intrahepatic cholangiocarcinoma, and chemotherapy (a combination of gemcitabine and S-1) was initiated. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "CASE REPORT: We report a case of RPLS associated with concurrent bevacizumab (Avastin), gemcitabine, and oxaliplatin use for unresectable intrahepatic cholangiocarcinoma. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "The intrahepatic cholangiocarcinoma cells were low sensitive to cisplatin and paclitaxel, but not sensitive to the other 4 chemotherapeutic drugs. ", "drug": "cisplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "A 62-year-old patient on sunitinib for intrahepatic cholangiocarcinoma developed a lesion on her right foot. ", "drug": "sunitinib", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Here we report three cases of patients with advanced intrahepatic cholangiocarcinoma progressive after standard chemotherapy and treated with sunitinib 50 mg/d in 6-wk cycles of 4 wk on treatment followed by 2 wk off treatment (Schedule 4/2). ", "drug": "sunitinib", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Those observations contributed to launch a prospective phase II multicenter trial investigating sunitinib in advanced intrahepatic cholangiocarcinoma (SUN-CK study; NCT01718327). ", "drug": "sunitinib", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIM: To report clinical outcomes of transarterial chemoembolization (TACE) using drug-eluting beads (DEBs) loaded with doxorubicin for the treatment of unresectable intrahepatic cholangiocarcinoma (CCA). ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Factors associated with disease-free survival (DFS) included intrahepatic cholangiocarcinoma (ICC) tumor size (P\u200a=\u200a0.002) and use of postoperative prophylactic transcatheter arterial chemoembolization (TACE) treatment (P\u200a=\u200a0.015). ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIM: To retrospectively evaluate the safety and efficacy of ultrasound-guided percutaneous microwave ablation (MWA) combined with simultaneous transarterial chemoembolization (TACE) in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC). ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " BACKGROUND: The effectiveness of adjuvant transarterial chemoembolization (TACE) for intrahepatic cholangiocarcinoma (ICC) after hepatectomy remains unclear. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " PURPOSE: To evaluate the detectability of intrahepatic cholangiocarcinoma (ICC) on dual-phase cone-beam CT (DPCBCT) during conventional transarterial chemoembolization (cTACE) compared to that of digital subtraction angiography (DSA) with respect to pre-procedure contrast-enhanced magnetic resonance imaging (CE-MRI) of the liver. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIMS: The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "RECENT FINDINGS: Locoregional therapy studies in patients with intrahepatic cholangiocarcinoma employing radiofrequency ablation (RFA), transarterial chemoembolization (TACE) or external as well as internal radiation therapy yielded promising results in the last couple of years. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " BACKGROUND: Effects of adjuvant transcatheter arterial chemoembolization (TACE) for intrahepatic cholangiocarcinoma (ICC) radical surgery have never been evaluated. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIM: To evaluate the clinical outcome and the survival benefits of transarterial chemoembolization (TACE) for unresectable intrahepatic cholangiocarcinoma (ICC) compared with supportive therapy. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " BACKGROUND: Image-guided transcatheter hepatic chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC) and for adequate preservation of liver function. ", "drug": "TACE", "disease": "Hepatocellular carcinoma"}, {"polarity": 1, "orig_sen": " BACKGROUND: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized studies. ", "drug": "TACE", "disease": "Hepatocellular carcinoma"}, {"polarity": 0, "orig_sen": "The feasibility and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Fifteen patients (8 with colorectal carcinoma liver metastases, 7 with intrahepatic cholangiocarcinoma) were treated with 27 sessions of OEM-TACE. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " BACKGROUND: The role of transcatheter arterial chemoembolization (TACE) or transcatheter arterial chemoinfusion (TACI) for unresectable intrahepatic cholangiocarcinoma (ICC) has recently been questioned. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " The purpose of this study was to evaluate the safety and efficacy of TACE with microspheres preloaded with doxorubicin in unresectable intrahepatic cholangiocarcinoma (UCH). ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " The aim of this retrospective study was to determine the safety and efficacy of chemoembolization (TACE) as palliative treatment for patients with unresectable intrahepatic cholangiocarcinoma (CCA) and to compare the results with those in the literature. ", "drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma"}]